BETOPTIC
Clinical safety rating: caution
Comprehensive clinical and safety monograph for BETOPTIC (BETOPTIC).
Selective beta-1 adrenergic receptor antagonist; reduces intraocular pressure by decreasing aqueous humor production.
| Metabolism | Hepatic metabolism primarily via CYP2D6 to inactive metabolites. |
| Excretion | Renal (fecal <5%). 60% as unchanged drug, 40% as inactive metabolites. |
| Half-life | Terminal elimination half-life: 4–5 hours. With topical ophthalmic administration, systemic absorption is minimal, so half-life refers to IV data. |
| Protein binding | 50–55% (primarily to albumin). |
| Volume of Distribution | 0.2–0.3 L/kg. Indicates moderate distribution into extravascular tissues, reflecting limited CNS penetration due to hydrophilicity. |
| Bioavailability | Ophthalmic: <10% (systemic absorption via nasolacrimal duct). Oral: 90% (but not used systemically). |
| Onset of Action | Ophthalmic: 30 minutes (reduction in intraocular pressure). |
| Duration of Action | Ophthalmic: 12 hours (IOP-lowering effect). Dosing twice daily maintains 24-hour control. |
Instill 1 drop of 0.5% solution in the affected eye(s) twice daily.
| Dosage form | SOLUTION/DROPS |
| Renal impairment | No dosage adjustment required for renal impairment. |
| Liver impairment | No dosage adjustment required for hepatic impairment. |
| Pediatric use | Safety and efficacy in pediatric patients have not been established. |
| Geriatric use | No specific dosage adjustment recommended; monitor for systemic effects. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for BETOPTIC (BETOPTIC).
| Breastfeeding | Betaxolol is excreted into breast milk in low concentrations. The milk-to-plasma ratio is approximately 1.7. Due to potential for infant bradycardia and hypotension, caution is advised. Monitor infant for signs of beta-blockade. |
| Teratogenic Risk | Betoptic (betaxolol) is a beta-blocker. Animal studies have shown no teratogenic effects, but human data are limited. Beta-blockers may cause fetal bradycardia, growth restriction, and hypoglycemia when used during the second and third trimesters. There is a risk of neonatal bradycardia and hypotension if used near term. Use only if clearly needed. |
■ FDA Black Box Warning
No FDA boxed warning.
| Serious Effects |
["Sinus bradycardia","Second- or third-degree atrioventricular block","Cardiogenic shock","Overt cardiac failure","Hypersensitivity to betaxolol or any component of the formulation"]
| Precautions | ["May exacerbate respiratory conditions (bronchospasm) in patients with asthma or COPD","Can mask symptoms of hypoglycemia in diabetic patients","May cause bradycardia or heart block; use caution in patients with sinus node dysfunction","May mask signs of hyperthyroidism","Caution in patients with cerebrovascular insufficiency"] |
| Food/Dietary | No significant food interactions. Avoid excessive alcohol consumption as it may lower blood pressure and increase systemic effects. |
Loading safety data…
| Fetal Monitoring | Monitor maternal heart rate and blood pressure. Assess fetal growth via ultrasound; monitor fetal heart rate after maternal dosing. Newborns should be observed for bradycardia, hypoglycemia, and respiratory depression for 48 hours after birth. |
| Fertility Effects | No specific studies on betaxolol and human fertility. Beta-blockers generally have not shown significant adverse effects on fertility in animal studies. |
| Clinical Pearls | Betoptic (betaxolol) is a cardioselective beta-blocker indicated for lowering intraocular pressure (IOP) in chronic open-angle glaucoma or ocular hypertension. Its beta-1 selectivity reduces the risk of bronchospasm, but caution is still advised in patients with reactive airway disease. Assess for systemic beta-blockade effects (bradycardia, hypotension) in susceptible patients, especially those on oral beta-blockers. Contact lens wearers should remove lenses before instillation and wait 15 minutes before reinsertion due to preservative (benzalkonium chloride) absorption. |
| Patient Advice | Shake the bottle well before each use. · Apply pressure to the inner corner of the eye (nasolacrimal occlusion) for 1-2 minutes after instillation to minimize systemic absorption. · Do not touch the dropper tip to the eye or any surface to avoid contamination. · If using more than one ophthalmic product, wait at least 5-10 minutes between applications. · Remove contact lenses before use and wait 15 minutes before reinserting. · Report any shortness of breath, wheezing, slow heart rate, or fainting to your doctor immediately. · Do not drive or operate machinery if you experience blurred vision after instillation. |